Core Scientific, Inc. Form 8-K Summary
Business Context and Reporting Period
Core Scientific filed this Current Report on October 30, 2023 under Item 7.01, Regulation FD. The company and certain affiliates remain debtors-in-possession in Chapter 11 bankruptcy proceedings filed on December 21, 2022 in the U.S. Bankruptcy Court for the Southern District of Texas. The company continues operating under Bankruptcy Court jurisdiction.
Its common stock and warrants trade exclusively on the OTC Pink Marketplace under the symbols CORZQ and CRZWQ, respectively.
Restructuring Update and Key Financial Matters
On October 30, 2023, the Debtors reached an agreement in principle with the ad hoc group of secured convertible noteholders and the official equity holders’ committee regarding the terms of a Chapter 11 plan of reorganization.
- The agreement is documented in a Restructuring Term Sheet.
- Implementation remains subject to finalizing a third amended joint Chapter 11 plan and related disclosure statement.
- The parties also expect to execute a restructuring support agreement and other definitive documentation.
- The filing does not provide current or period-specific revenue, profit, cash flow, margin, debt balance, or liquidity amounts.
Material Changes Versus the Prior Comparable Period
The principal development is the October 30 agreement in principle, following a mediated settlement reached on September 19, 2023 and earlier proposed and amended Chapter 11 plans filed between June and September 2023. The company had not yet executed the restructuring support agreement or finalized the contemplated plan as of the filing date.
Outlook, Risks, and Unusual Items
- The company expects to enter into the restructuring support agreement and related definitive documents in the coming days, but provides no assurance that this will occur.
- Emergence from Chapter 11 and achievement of significant cash flows from operations remain subject to substantial uncertainty.
- Key risks include Bankruptcy Court approval, potential third-party motions, the duration and effects of the Chapter 11 cases, adverse effects on liquidity and operations, and increased legal and professional costs.
- The filing identifies risks related to finalizing and obtaining a replacement debtor-in-possession facility, satisfying conditions to debtor-in-possession financing, and potential acceleration of debt obligations.
- Trading on the OTC Pink Marketplace may involve significant price volatility and liquidity risks.
- The term sheet and press release are furnished as exhibits and are not deemed filed for purposes of Exchange Act Section 18 liability or incorporated by reference into other filings.
Investor Verification Checklist
- Verify execution of the restructuring support agreement and other definitive restructuring documents.
- Review the final third amended Chapter 11 plan, disclosure statement, and Restructuring Term Sheet in Exhibit 99.2.
- Confirm Bankruptcy Court approval, creditor and equity-holder treatment, and any changes to capital structure or securities.
- Assess the status, terms, and conditions of the replacement debtor-in-possession financing.
- Review subsequent filings for liquidity, debt obligations, operating cash flows, bankruptcy costs, and the timing and terms of any emergence from Chapter 11.